Celgene Corp. (NQ: CELG)
141.51 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 8:10 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(CELG) Community Analysis from
April 21, 2014
(Jutia Group, 3/21/14)
[Reuters] - U.S. health regulators on Friday approved a Celgene Corp drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease...(read more)
(Jutia Group, 4/1/14)
[Business Wire] - Celgene Corporation will host a conference call and live audio webcast on Thursday, April 24, 2014 at 9 a.m. ET to discuss...(read more)
(The Market Financial, 12/10/13)
There has been constant talk about the overall market being in a bubble. Is it a bubble? To some extent yes, however there is one particular sector that is in the...(read more)
Celgene (CELG) Company Overview

Celgene (NYSE:CELG) is a pharmaceutical company that develops and sells drugs to treat blood cancers. Its main drugs include Thalomid, which is used to treat multiple myeloma, a cancer of the plasma cell in blood; Revlimid, which is a first-line treatment for myelodysplastic syndrome (MDS); and a family of Ritalin drugs, which are used to treat Attention Deficit Disorder (ADHD). The company generated $2.6 billion in revenue and $777 million in net income in 2009.[1]

However, Revlimid will face its stiffest competition yet when rival company Millemnium's new drug Velcade is approved for use in first-line treatment of multiple myeloma. Velcade has shown much greater efficacy as a first-line treatment in its clinical trials, surpassing the performance of Revlimid, which means it will compete fiercely with Revlimid after it receives FDA approval and enters the market.

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here